Feb 20, 2024 8:30 am EST Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
Jan 24, 2024 9:15 am EST Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
Dec 11, 2023 9:00 am EST Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
Nov 14, 2023 4:05 pm EST Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Nov 07, 2023 9:15 am EST Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14
Oct 19, 2023 4:01 pm EDT Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program
Oct 10, 2023 9:00 am EDT Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society
Sep 29, 2023 7:30 am EDT Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy